Streetbeat News

MDAI

Spectral AI, Inc.

https://www.spectral-ai.com

Industry

Medical - Devices

Spectral AI, Inc. operates as an artificial intelligence (AI) company. The company focuses on medical diagnostics for faster and accurate treatment decisions in wound care with applications involving patients with burns and diabetic foot ulcers. Its products include DeepView, a predictive diagnostic device that offers clinicians an objective and immediate assessment of a wound's healing potential prior to treatment or other medical intervention. The company is based in Dallas, Texas.

Open

1.41

Mkt cap

33M

Volume

230K

High

1.56

P/E Ratio

-2.46

52-wk high

3.25

Low

1.40

Div yield

N/A

52-wk low

0.82

Spectral AI Inc (NASDAQ:MDAI) plans to spin off its subsidiary, Spectral IP, Inc., to focus on IP monetization and healthcare AI expansion. The deal with Sauvegarder Investment Management, Inc. aims to position Spectral IP as an independent company targeting various sectors.

Portfolio Pulse from

November 06, 2024 | 2:15 pm

Spectral AI plans to spin off its Spectral IP subsidiary to focus on intellectual property investments and monetization. This strategic move aims to unlock IP value and sharpen the company's focus on AI medical diagnostics.

Portfolio Pulse from

November 06, 2024 | 1:15 pm

Spectral AI, Inc. (NASDAQ:MDAI) has completed its U.S. Burn Pivotal Study, a major step towards FDA submission for its DeepView AI-Burn system in 2025. This system aims to improve burn wound diagnostics.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 12:14 pm

Spectral AI's CEO, Peter Carlson, has resigned, and the company has established an Office of the Chairman, as per an SEC filing.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 1:28 pm

Spectral AI shares rose following the announcement that Dr. J. Michael DiMaio, the company's founder, has been appointed as Chairman.

Portfolio Pulse from Benzinga Newsdesk

October 14, 2024 | 8:09 pm

Spectral AI has appointed its founder, Dr. J. Michael DiMaio, as the new Chairman of the company. This leadership change could influence the company's strategic direction.

Portfolio Pulse from Benzinga Newsdesk

October 14, 2024 | 8:08 pm

Spectral AI, Inc. (NASDAQ:MDAI) has completed a proof-of-concept module for its wound measurement technology, which calculates the total body surface area of burns. This technology, integrated into the DeepView® System, aims to improve the speed and accuracy of burn size estimation, crucial for acute burn management.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 12:13 pm

Spectral AI has achieved 25% patient enrollment in its US Burn Pivotal Study and has added two new clinical trial sites. This progress is significant for the company's research and development efforts.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 12:17 pm

Spectral AI plans to submit a De Novo request for its DeepView AI-Burn device to be classified as a Class II medical device by Q2 2025.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 12:05 pm

Spectral AI has received an $850K award from the Medical Technology Enterprise Consortium to further develop its AI-driven DeepView SnapShot M for assessing battlefield burn wounds. This brings its total non-dilutive government funding to over $7 million.

Portfolio Pulse from Benzinga Newsdesk

September 05, 2024 | 12:24 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.